For more than twenty years, there was one thing Medicare would not pay for, no matter what: prescription drugs used purely for weight loss. As of July 1, 2026, that has changed. Through a new program called the Medicare GLP-1 Bridge, eligible beneficiaries can now get popular weight-loss medications like Wegovy and Zepbound for a $50 monthly copay, instead of the $1,000 or more they can cost at the pharmacy counter.
It’s a big shift, and it has also created a lot of confusion. Which drugs are covered? Does this include Ozempic? Who qualifies, and what happens next year? Let’s walk through exactly what the GLP-1 Bridge does and doesn’t do, in plain English.
At The Medicare Family, we help people cut through exactly this kind of confusion so they can make confident decisions. If you’re wondering whether your plan covers these medications, or want help finding one that does, schedule your FREE call to talk with a licensed Medicare expert, at no cost or pressure.
What Is the Medicare GLP-1 Bridge Program?
When Congress created Medicare’s prescription drug benefit back in 2003, it specifically excluded drugs used for weight loss. For years, that meant beneficiaries who wanted medications like Wegovy strictly to lose weight had to pay full price out of pocket, often more than $1,000 a month.
The GLP-1 Bridge is a temporary Medicare program designed to work around that long-standing exclusion. Beginning July 1, 2026, eligible members of a Medicare drug plan can get certain GLP-1 weight-loss medications for a flat $50 monthly copay. It’s called a “bridge” because it’s meant to be a starting point that leads into a larger, longer-term program expected in 2027. For the first time in Medicare’s history, weight-loss drugs are on the table.
Which Weight-Loss Drugs Are Covered, and What They Cost
The Bridge covers GLP-1 medications that are FDA-approved for weight loss. Right now, that means:
- Wegovy (semaglutide), available as both an injection and a tablet
- Zepbound (tirzepatide)
Exactly which drugs and formulations are available can vary from plan to plan, so it’s always worth confirming with your specific plan. The headline number, though, is the same across the board: eligible beneficiaries pay a $50 copay for a 30-day supply, compared with the roughly $1,000-plus these drugs can cost at list price.
One detail to keep in mind: the Bridge runs as a separate Medicare program rather than through your regular Part D benefit, so it works a little differently from your other prescription coverage. It’s a good idea to confirm the specifics, including how the copay applies, with your plan before you count on it.
Who Qualifies for the GLP-1 Bridge?
Qualifying comes down to a few things:
- You’re enrolled in a Medicare drug plan. That means either a standalone Part D plan or a Medicare Advantage plan that includes drug coverage.
- Your plan is participating. Plans have to opt in to the program, so not every Part D or Medicare Advantage plan offers it. This is the step that catches the most people off guard.
- You meet the medical criteria. The program is generally aimed at adults living with obesity, or those who are overweight with a related health condition. Your doctor confirms that you qualify by submitting a prior authorization request to Medicare.
If any one of those pieces is missing, coverage under the Bridge may not apply, which is exactly why it pays to check the details rather than assume.
What the Bridge Doesn’t Cover (Including Ozempic for Weight Loss)
Here’s where a lot of the online confusion comes in. The most important thing to understand is that the Bridge covers drugs approved for weight loss, not every GLP-1 medication.
That’s why Ozempic is not part of the program. Ozempic is FDA approved to treat type 2 diabetes, and Medicare Part D has always covered it for that purpose, subject to your plan’s drug list and rules. If you take a GLP-1 for a medical condition, such as Ozempic for diabetes or Wegovy to lower the risk of a heart attack or stroke, that coverage runs through your regular Part D plan, not the Bridge.
The simple way to keep it straight: the GLP-1 Bridge is for a weight-loss prescription, while your standard Part D plan handles GLP-1s prescribed for diabetes or heart health. Which path applies to you depends on why the drug was prescribed.
What Happens After 2026?
The GLP-1 Bridge is temporary. Medicare has said it plans to move to a longer-term program, known as the BALANCE Model, in 2027, which is expected to build GLP-1 coverage into participating drug plans in a more permanent way.
The catch, and it’s an important one: if you start on the Bridge this year, your coverage will not automatically carry over into 2027. You’ll need to make sure your 2027 plan participates in the new program. The time to check that is during Medicare’s Annual Enrollment Period, which runs October 15 to December 7, 2026. This is precisely the kind of plan-specific detail that trips people up, and it’s worth putting on your calendar now.
How to Make Sure You’re Actually Covered
Because so much depends on your particular plan, a little homework goes a long way. Before you count on coverage, it’s worth confirming three things:
- Whether your current plan is participating in the GLP-1 Bridge
- Whether it covers the specific medication your doctor prescribed
- Whether your 2027 plan will continue that coverage under the new program
If that sounds like a lot to track down, it doesn’t have to be. A licensed Medicare advisor can check plan participation and drug lists for you and flag anything you’ll want to revisit at Annual Enrollment, all at no cost. And of course, whether one of these medications is right for you in the first place is a conversation for you and your doctor.
Frequently Asked Questions
Does Medicare cover Ozempic for weight loss now?
No. Ozempic isn’t part of the GLP-1 Bridge, because the Bridge only covers drugs approved for weight loss. Ozempic is approved for type 2 diabetes, and Medicare Part D covers it for that purpose (subject to your plan’s rules). The Bridge covers weight-loss-approved drugs like Wegovy and Zepbound.
How much do weight-loss drugs cost under Medicare now?
Eligible beneficiaries pay a $50 copay for a 30-day supply through the GLP-1 Bridge, compared with the roughly $1,000 or more these medications can cost at list price.
Who qualifies for the GLP-1 Bridge program?
You need to be enrolled in a Medicare drug plan that is participating in the program, and you need to meet the medical criteria, generally adults with obesity or those who are overweight with a related condition. Your doctor confirms eligibility through a prior authorization request.
Will this coverage continue in 2027?
Not automatically. The Bridge is a temporary program, and Medicare plans to transition to a longer term option (the BALANCE Model) in 2027. If you start on the Bridge, you’ll want to confirm your 2027 plan during the Annual Enrollment Period (October 15 to December 7, 2026).
The Takeaway
After more than two decades, Medicare is finally helping cover weight-loss medications, and for eligible beneficiaries, a $50 copay in place of a four-figure pharmacy bill is a real change. But the fine print matters: your plan has to participate, only certain drugs are included, Ozempic for weight loss isn’t among them, and coverage isn’t guaranteed to continue into 2027. Knowing how the program works puts you in a position to actually take advantage of it.
At The Medicare Family, we’ve spent more than 40 years helping people across all 50 states understand Medicare in plain English and find coverage that fits their lives, at no cost to them. If you’d like help checking whether your plan covers these medications, or finding one that does, schedule your FREE call today. You can also confirm your plan’s drug list any time on Medicare.gov.
